Ublituximab is a monoclonal antibody that targets a unique epitope on the CD20 antigen. Ublituximab has been used as a medication indicated for the treatment of multiple sclerosis (MS).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.